{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:56:02Z","timestamp":1790927762957,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gen Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Pulmonary metastasectomy (PM) is an established treatment for selected patients with pulmonary metastases. While systemic therapies such as immune checkpoint inhibitors, and stereotactic radiation have become standard for unresectable or metastasized melanoma patients, no randomized controlled trials directly assess the benefit of PM by itself in oligometastatic melanoma patients with lung metastases. This retrospective study compares long-term survival outcomes in patients undergoing PM versus those receiving non-surgical therapy for pulmonary metastatic melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed melanoma patients from the skin cancer center Cologne who were treated with curative intent for their primary tumor and later developed isolated pulmonary metastases. Patients in the non-surgical group had biopsy-confirmed lung metastases. Survival outcomes between patients undergoing PM and those receiving non-surgical therapies were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between 2012 and 2020, 87 patients met the inclusion criteria: 49 underwent PM and 38 received non-surgical therapy. The number of pulmonary metastases differed significantly between groups (1.27\u2009\u00b1\u20090.57 vs. 3.2\u2009\u00b1\u20091.1;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). BRAF-mutations were more common in the non-surgical group (35.4% vs. 55.3%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04).\n                    <\/jats:p>\n                    <jats:p>\n                      Patients undergoing PM showed significantly improved 3-year (88.0% vs. 65.7%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) and 5-year survival rates (81.3% vs. 30.8%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) compared to the non-surgical group. Kaplan\u2013Meier analysis confirmed prolonged overall survival in the PM group (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.02). However, among patients with BRAF mutations, survival did not differ significantly between the groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.09).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PM is associated with favorable overall survival. These findings support considering PM as a treatment option in selected patients to improve long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11748-026-02310-x","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:52:44Z","timestamp":1780307564000},"page":"992-1003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pulmonary metastasectomy for malignant melanoma prolongs survival significantly compared to non-surgical therapy"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7118-8432","authenticated-orcid":false,"given":"Georg","family":"Schlachtenberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Goitom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Amorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lopez Pastorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julika","family":"Merres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gaisendrees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias B.","family":"Heldwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2310_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet (London, England). 2023;402:485\u2013502.","journal-title":"Lancet (London, England)"},{"key":"2310_CR2","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472\u201392.","DOI":"10.3322\/caac.21409"},{"key":"2310_CR3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/ejcts\/ezz211","volume":"56","author":"J Viehof","year":"2019","unstructured":"Viehof J, Livingstone E, Loscha E, Stockhammer P, Bankfalvi A, Pl\u00f6nes T, et al. Prognostic factors for pulmonary metastasectomy in malignant melanoma: size matters. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2019;56:1104\u20139.","journal-title":"Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg"},{"key":"2310_CR4","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.21037\/jtd.2020.03.120","volume":"13","author":"CY Bong","year":"2021","unstructured":"Bong CY, Smithers BM, Chua TC. Pulmonary metastasectomy in the era of targeted therapy and immunotherapy. J Thorac Dis. 2021;13:2618\u201327.","journal-title":"J Thorac Dis"},{"key":"2310_CR5","first-page":"193","volume":"181","author":"A Barth","year":"1995","unstructured":"Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193\u2013201.","journal-title":"J Am Coll Surg"},{"key":"2310_CR6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.athoracsur.2018.06.078","volume":"106","author":"TP Hanna","year":"2018","unstructured":"Hanna TP, Chauvin C, Miao Q, Rizkalla M, Reid K, Peng Y, et al. Clinical outcomes after pulmonary metastasectomy for melanoma: a population-based study. Ann Thorac Surg. 2018;106:1675\u201381.","journal-title":"Ann Thorac Surg"},{"key":"2310_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1054\/bjoc.2000.1335","volume":"83","author":"F Leo","year":"2000","unstructured":"Leo F, Cagini L, Rocmans P, Cappello M, Geel AN, Maggi G, et al. Lung metastases from melanoma: When is surgical treatment warranted? Br J Cancer. 2000;83:569\u201372.","journal-title":"Br J Cancer"},{"key":"2310_CR8","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.3390\/cancers15092462","volume":"15","author":"E Meacci","year":"2023","unstructured":"Meacci E, Nachira D, Congedo MT, Ibrahim M, Pariscenti G, Petrella F, et al. Surgical resection of pulmonary metastases from melanoma in oligometastatic patients: results from a multicentric study in the era of immunoncology and targeted therapy. Cancers. 2023;15:2462.","journal-title":"Cancers"},{"key":"2310_CR9","doi-asserted-by":"publisher","first-page":"ezac098","DOI":"10.1093\/ejcts\/ezac098","volume":"62","author":"G Schlachtenberger","year":"2022","unstructured":"Schlachtenberger G, Doerr F, Menghesha H, Heldwein MB, Lauinger P, Wolber P, et al. Pulmonary metastasectomy for metastatic head and neck cancer prolongs survival significantly compared to non-surgical therapy. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2022;62:ezac098.","journal-title":"Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg"},{"key":"2310_CR10","first-page":"S187","volume":"5","author":"A Oliaro","year":"2010","unstructured":"Oliaro A, Filosso PL, Bruna MC, Mossetti C, Ruffini E. Pulmonary metastasectomy for melanoma. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2010;5:S187\u201391.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"2310_CR11","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet (London, England). 2017;390:1853\u201362.","journal-title":"Lancet (London, England)"},{"key":"2310_CR12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol Off J Eur Soc Med Oncol. 2019;30:582\u20138.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2310_CR13","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/JCO.23.01136","volume":"41","author":"R Seth","year":"2023","unstructured":"Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, et al. Systemic therapy for melanoma: ASCO guideline update. J Clin Oncol. 2023;41:4794\u2013820.","journal-title":"J Clin Oncol"},{"key":"2310_CR14","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2019;30:1884\u2013901.","journal-title":"Ann Oncol"},{"key":"2310_CR15","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","volume":"31","author":"U Keilholz","year":"2020","unstructured":"Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:1435\u201348.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2310_CR16","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.athoracsur.2009.08.033","volume":"88","author":"L Erhunmwunsee","year":"2009","unstructured":"Erhunmwunsee L, D\u2019Amico TA. Surgical management of pulmonary metastases. Ann Thorac Surg. 2009;88:2052\u201360.","journal-title":"Ann Thorac Surg"},{"key":"2310_CR17","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s13063-019-3837-y","volume":"20","author":"T Treasure","year":"2019","unstructured":"Treasure T, Farewell V, Macbeth F, Monson K, Williams NR, Brew-Graves C, et al. Pulmonary metastasectomy versus continued active monitoring in colorectal cancer (PulMiCC): a multicentre randomised clinical trial. Trials. 2019;20:718.","journal-title":"Trials"},{"key":"2310_CR18","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/1097-0142(19840315)53:6<1299::AID-CNCR2820530613>3.0.CO;2-4","volume":"53","author":"GJ Hill 2nd","year":"1984","unstructured":"Hill GJ 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer. 1984;53:1299\u2013305.","journal-title":"Cancer"},{"key":"2310_CR19","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","volume":"17","author":"PB Chapman","year":"1999","unstructured":"Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17:2745\u201351.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2310_CR20","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20:1366\u201379.","journal-title":"Cancer Biol Ther"},{"key":"2310_CR21","doi-asserted-by":"crossref","unstructured":"Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C et al. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. The New England journal of medicine 2025.","DOI":"10.1056\/NEJMoa2502931"},{"key":"2310_CR22","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346.","journal-title":"N Engl J Med"},{"key":"2310_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, Heinzerling L, Aberle J, B\u00e4hr O, Eigentler TK, Grimm MO, et al. Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36\u201349.","journal-title":"Cancer Treat Rev"},{"key":"2310_CR24","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.1038\/ncomms6694","volume":"5","author":"GV Long","year":"2014","unstructured":"Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, et al. Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 2014;5:5694.","journal-title":"Nat Commun"},{"key":"2310_CR25","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"2310_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2018.08.008","volume":"103","author":"MJF Smith","year":"2018","unstructured":"Smith MJF, Smith HG, Joshi K, Gore M, Strauss DC, Hayes AJ, et al. The impact of effective systemic therapies on surgery for stage IV melanoma. Eur J Cancer. 2018;103:24\u201331.","journal-title":"Eur J Cancer"},{"key":"2310_CR27","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/jso.23938","volume":"111","author":"M He","year":"2015","unstructured":"He M, Lovell J, Ng BL, Spillane J, Speakman D, Henderson MA, et al. Post-operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of pre-operative treatment and elective indication. J Surg Oncol. 2015;111:980\u20134.","journal-title":"J Surg Oncol"}],"container-title":["General Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-026-02310-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11748-026-02310-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-026-02310-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:35:37Z","timestamp":1790926537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11748-026-02310-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2310"],"URL":"https:\/\/doi.org\/10.1007\/s11748-026-02310-x","relation":{},"ISSN":["1863-6705","1863-6713"],"issn-type":[{"value":"1863-6705","type":"print"},{"value":"1863-6713","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None declared.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}